[Preprint] Observational study finds single-dose Johnson & Johnson vaccine is 76.7% effective in preventing SARS-CoV-2 infection
13 May, 2021 | 06:06h | UTCReal-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19 – The Lancet
Commentary on Twitter
One of the first studies to assess real-world effectiveness of the J&J 1-dose vaccine, matches Phase 3 clinical trial, at 77%https://t.co/3YgcML9YSh @MayoClinic @MayoClinicHS preprint pic.twitter.com/XOjQlUaHK2
— Eric Topol (@EricTopol) May 11, 2021